button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 certainty unassessablestatistically conclusive-53% certainty unassessablestatistically conclusive-52%-
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 certainty unassessable+6% certainty unassessable+15%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons